Dr. Xiuning Le MD PhD at #TexasLung24 gives a brilliant breakdown of frontline #EGFR combination strategies including adding amivantamab to TKI (MARIPOSA) and targeting VEGF (RAMOSE). TLC Conference

In beautiful Austin for Texas Lung Conference #TexasLung24 TLC Conference with colleagues from all around the nation and from MDACC MD Anderson Cancer Center Eric K. Singhi, MD Marcelo Negrao Lauren Averett Byers, MD Stephen V Liu, MD Heather Wakelee Jhanelle Gray MD Julia Rotow MD LudaBazhenovaMD

Wonderful start at #AACR24 with colleagues MD Anderson Cancer Center Scott Kopetz David S. Hong MD and Chris Flowers.

#ASCO Educational Book with
Stephanie Saw Jordi Remon Lizza Hendriks
Look forward to this year's ASCO educational sessions.
EGFR Resisters Exon 20 Group, a multi-stakeholder organization MD Anderson Cancer Center

A wonderful meeting #ELCC24 #myESMO with Thoracic Oncologists Stephen V Liu, MD Misako Nagasaka Alfredo Addeo MD Lecia Sequist, MD, MPH H. Jack West, MD Herbert Loong Viola Zhu . Work colleagues become friends, and now feels almost like family ! Love my thoracic community.

I met up with my dear friend Prof. Richard White richard white at Oxford University, UK. We were both in Dr. Len Zon lab training years ago and now we are both professors in major institutions, and involved with Damon Runyon Cancer Research Foundation. Rich's side job is a tour guide.

Bayer wins FDA breakthrough therapy designation for NSCLC candidate
pharmaceutical-technology.com/news/bayer-win… via Pharma Technology Focus

This data is quite thought-provoking with L858R pts benefiting from the addition of ramucirumab to EGFR TKI.

Happy Lunar New Year 2024! May the Year of the Dragon be filled with confidence and courage! Wishing you and your family all prosperity and joy.

Looking forward to Santa Monica #TTLC24 Lauren Averett Byers, MD Eric K. Singhi, MD

Blueprint Medicines issued press release: “Discontinue further investment in the early clinical stage therapies BLU 945 and 451 for EGFR
NSCLC & explore strategic options including potential outlicensing”

Blu-945 & Blu-451 clinical trials will close

ir.blueprintmedicines.com/news-releases/…

A new trial activated at MDACC classic.clinicaltrials.gov/ct2/show/NCT05…
A novel MET TKI (ABN401) for METex14 NSCLC pts. Preliminary efficacy ORR 75% in TKI-naive pts and very favorable toxicity profile. Lauren Averett Byers, MD Eric K. Singhi, MD METCrusaders Exon 20 Group, a multi-stakeholder organization

This is our MDACC single-center cohort of EGFR-transformed SCLC (n=34). Del19 higher risk. Continuation of osimertinib didn't prolong OS. Bing-nan Zhang Eric K. Singhi, MD Lauren Averett Byers, MD EGFR Resisters Exon 20 Group, a multi-stakeholder organization
Brief Report: JTO Clinical and Research Reports jtocrr.org/article/S2666-…

This multi-center real-world analysis was such a team work David Gandara Jonathan Riess, MD MS Stephen V Liu, MD Heather Wakelee Marcelo Negrao Catherine A. Shu, MD. Also reflecting US practice pattern of using Amivantamab in all four subclasses of EGFR-mut NSCLC.

Highest honor I imagine receiving! My clinical care team ranked in the top 1% nationally for exceptional communication with patients and families for 2023. My teammates and dear friends, Jennifer Owens APN, Bryan John, RN, Justin Esguerra, Pt Service Coordinator. MD Anderson Cancer Center

Our paper is available on line now: Tepotinib in patients with NSCLC with high-level MET amplification detected by liquid biopsy: ORR 42% DoR 14.3 months. METCrusaders MD Anderson Cancer Center Exon 20 Group, a multi-stakeholder organization
VISION Cohort B: Cell Reports Medicine cell.com/cell-reports-m…

I had a very productive and thought-provoking time at Conquer Cancer, the ASCO Foundation ASCO retreat 2023, Lillian Siu, Dr. 'Skip' Burris, Dr. Steven Rosen. Deborah Doroshow Wade Iams Sandip Patel MD

I had this wonderful opportunity to present and discuss the newest lung cancer data from #myESMO @esmo23 with three leaders across the global, Prof. Tetsuya Mitsudomi, Dr. Pasi Janne, Dr. Li Zhang. MD Anderson Cancer Center

#LungCancerAwarenessMonth Dr. Singhi discusses three myths about lung cancer. MD Anderson Cancer Center

Such a memorable #ESMO23 ESMO - Eur. Oncology flying back with my fellow thoracic oncologists. MD Anderson Cancer Center Sandip Patel MD